惯性聚合 高效追踪和阅读你感兴趣的博客、新闻、科技资讯
阅读原文 在惯性聚合中打开

推荐订阅源

大猫的无限游戏
大猫的无限游戏
MyScale Blog
MyScale Blog
雷峰网
雷峰网
量子位
小众软件
小众软件
OSCHINA 社区最新新闻
OSCHINA 社区最新新闻
博客园 - 叶小钗
T
Tailwind CSS Blog
月光博客
月光博客
博客园 - 【当耐特】
博客园_首页
罗磊的独立博客
博客园 - 三生石上(FineUI控件)
IT之家
IT之家
爱范儿
爱范儿
阮一峰的网络日志
阮一峰的网络日志
钛媒体:引领未来商业与生活新知
钛媒体:引领未来商业与生活新知
WordPress大学
WordPress大学
The Cloudflare Blog
freeCodeCamp Programming Tutorials: Python, JavaScript, Git & More
S
SegmentFault 最新的问题
人人都是产品经理
人人都是产品经理
V
V2EX
酷 壳 – CoolShell
酷 壳 – CoolShell

All Articles on Seeking Alpha

All Eyes On Cencora, A Healthcare Supplier That Could See Lots More Upside Simply Good Foods Doesn't Look Like A Growth Stock Anymore Applied Digital: Post-Earnings Clarity Confirms An Accelerated Path To $1 Billion NOI Target IBIT: Why I Stepped To The Side (Technical Analysis) (Rating Downgrade) XES: Oil Service Stocks Turn Pricey; Why It's Time To Take Profits (Rating Downgrade) The Only Dividend Strategy I'd Trust In A 3.5% Fed Funds World Opera: AI-Driven Advertising Prospects - Upside Potential And Rich Dividend Yields RenaissanceRe: Preferred Stock Hasn't Been This Appealing In Years Q1 Earnings Kick Off With Major Banks' Results: Bank of America, Netflix In Focus Sezzle: Consolidation Completed, Re-Rating Ahead Bitmine Immersion Q2 Preview: Ethereum Thesis Facing Important Report Card I Am Sharing 2 Of My Retirement High-Yield Gems The Software Narrative Is Leaking Badly Again Thanks To Anthropic Mythos The Muni Market Looks Appealing In Q2 AVIV: Should Keep Rising If The Ceasefire Holds Foundayo Explained: Lilly's New Weight Loss Pill And The Amazon Effect Sabesp: A New Privatization As An Opportunity! EchoStar: Potential Bull Trap At Play - Take Gains Off The Table Teladoc Health: Improving Fundamentals Support A Turnaround Story March CPI Inflation: 5 Reasons To Stay Calm Two 12%+ Yielding BDC Bargains (One Is My Top Deep-Value Pick) TechnipFMC: We Prefer Saipem With More Room To Improve Tesla: From Bye-Bye To Buy-Buy (Rating Upgrade) DMB: Vulnerable To High Interest Rates Western Midstream: A 9% Yield That Still Grows In A Downturn IQQQ: Tax-Efficient Income From The Nasdaq But Does Not Protect Against Declines Qualys Share Price Pulled Down By Potential Cybersecurity Disruptor S&P 500: A Dead Money Era May Be Here. How To Thrive In It Vistance Networks Looks Better Than Before With Powerful Earnings Growth Commerce Bancshares: Valuation, Not Quality, Is The Problem
Teva's Growth Story Is No Longer Just Generic, It's Getti...
Willow Tree Research · 2026-05-25 · via All Articles on Seeking Alpha

Summary

  • Teva Pharmaceutical delivered a strong Q1 2026, reinforcing my buy rating and the company's successful pivot to innovative growth assets.
  • TEVA's innovative neuroscience franchise—AUSTEDO, AJOVY, and Uzedy—drove $838M in Q1 revenue, up 41% year over year, offsetting legacy generics decline.
  • Management maintained full-year guidance, with stable gross margins (52.9%) and a clear path to 30% non-GAAP operating income margin by 2027.
  • Pipeline credibility is rising, biosimilars are gaining traction, and the pending Emalex acquisition adds further innovative growth optionality.
Doctor sharing medical results with woman

Morsa Images/DigitalVision via Getty Images

TEVA Q1 2026 Earnings update: reinforcing my buy rating

Teva (TEVA) delivered a robust Q1 2026 print, further substantiating the company's pivot to growth strategy and my thesis from my initiation

5.35K Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in TEVA, TEVJF over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

I do not provide personal investment advice. All content in this article, including but not limited to opinions, analyses, commentaries, forecasts, stock picks, and investment strategies, is for informational and educational purposes only and should not be interpreted as financial or investment advice. While I strive to provide accurate and up-to-date information, the content may contain errors, inaccuracies, or omissions. Any financial decisions or investments made based on the information presented in this article are solely at your own risk. I am not responsible for any financial losses, damages, or other consequences resulting from actions taken in reliance on the information provided. You should conduct your own due diligence and consult with a qualified financial professional before making any investment decisions. This article reflects my personal views and opinions and is not affiliated with any employer, financial institution, or advisory firm. No representations or warranties are made regarding the completeness, accuracy, or reliability of the content, including any external links provided. Any third-party links are for informational purposes only, and I do not endorse or take responsibility for the content or services offered by external sources. All information is provided on an "as is" basis without any express or implied warranties.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.